Epic Medical Research, a Dallas-based clinical research organization, has become the latest member of hyperCORE International's global partner site network. This partnership is set to bolster Epic's capabilities in conducting comprehensive clinical trials across a wide range of therapeutic areas, including metabolic disorders, fatty liver disease, and neurological conditions, among others. With state-of-the-art facilities and a dedicated laboratory for end-to-end PBMC processing, Epic is well-positioned to contribute significantly to hyperCORE's mission of advancing clinical research.
Dr. Haresh Boghara, President & Principal Investigator at Epic Medical Research, expressed enthusiasm about the collaboration, highlighting the access to greater resources and shared expertise that hyperCORE International offers. This partnership is expected to enhance the quality and efficiency of clinical trials, ultimately benefiting patient outcomes. Nicholas Focil, President of hyperCORE International, also commended Epic's commitment to quality and innovation, which aligns with hyperCORE's objectives of delivering streamlined operations and accelerated results in clinical research.
hyperCORE International, established in 2019, is a network of leading clinical research site organizations with over 80 active trial sites across five countries. The network has completed more than 7,000 studies involving over 140,000 participants, demonstrating its significant impact on the global clinical research landscape. The addition of Epic Medical Research to this network is a testament to hyperCORE's ongoing commitment to fostering collaborations that enhance the efficiency, standardization, and excellence of clinical trials. For more information on hyperCORE International, visit https://www.hypercoreinternational.com.
